 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pancreatic Cancer Battle Boosted by $200M VC Firm Pancreatic Cancer Battle Boosted by $200M VC Firm PR Newswire VANCOUVER, BC, Sept. 19, 2023 FN Media Group Presents USA News Group News Commentary...

Pancreatic Cancer Battle Boosted by $200M VC Firm

This is a Bearish indicator signaling MACK's price could decline from here. Traders may explore shorting the stock or put options...

Merrimack Pharmaceuticals (MACK, $12.27) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 13, 2023

This is a Bullish indicator signaling MACK's price could rise from here. Traders may explore going long the stock or buying call options...

Merrimack Pharmaceuticals (MACK, $12.36) Moving Average Convergence Divergence (MACD) Histogram turned positive on September 12, 2023

Merrimack Pharmaceuticals (MACK, $12.25) Moving Average Convergence Divergence (MACD) Histogram turned negative on September 6, 2023

Merrimack Pharmaceuticals (MACK, $12.07) Moving Average Convergence Divergence (MACD) Histogram turned negative on August 23, 2023

Related Stocks: MACK, PLOW, ECVT, VTOL, DOLE...

Western Standard LLC Boosts Stake in Merrimack Pharmaceuticals Inc

This price move could be a signal that MACK may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Merrimack Pharmaceuticals (MACK, $12.49) price may drop as it broke higher Bollinger Band on Aug 10, 2023

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Get Free Report) Director Eric Andersen acquired 134,493 shares of the stock in a transaction on Monday, August 7th. The stock was bought at an average price of $12.00 per share, with a total value of $1,613,916.00. Following the transaction, the ...

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Buys $1,613,916.00 in Stock

This is a signal that MACK's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Merrimack Pharmaceuticals (MACK, $12.37) RSI Indicator left the overbought zone on August 11, 2023

Merrimack Pharmaceuticals (MACK, $12.49) RSI Indicator left the overbought zone on August 10, 2023

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Watchers	8,258
52-Wk Low	$3.00
52-Wk High	$13.66

Market Cap	$174.86M
Volume (M)	297.00
52-Wk High	$13.66
52-Wk Low	$3.00

MACK Merrimack Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals